Vaxcyte (PCVX) Gains from Investment Securities (2019 - 2026)
Vaxcyte (PCVX) reported Gains from Investment Securities of $9.3 million for Q1 2026, up 75.71% year-over-year from $5.3 million in Q1 2025, and up 823.04% quarter-over-quarter from $1.0 million in Q4 2025.
Vaxcyte (PCVX) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has 8 years of Gains from Investment Securities data on file, last reported at $9.3 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $9.3 million, up 75.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (down 7.86% YoY), and the FY2025 annual result was $11.0 million, down 23.1% from the prior year.
- Gains from Investment Securities climbed to $9.3 million in Q1 2026 per PCVX's latest filing, from $1.0 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $9.3 million in Q3 2024 and troughed at -$7.4 million in Q4 2023.
- A 5-year average of $1.6 million and a median of $1.0 million in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities slumped 200.6% in 2022, then surged 25331.76% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$6.5 million in 2022, then dropped by 13.53% to -$7.4 million in 2023, then surged by 114.61% to $1.1 million in 2024, then dropped by 7.19% to $1.0 million in 2025, then surged by 823.04% to $9.3 million in 2026.
- Business Quant data shows PCVX's Gains from Investment Securities at $9.3 million in Q1 2026, $1.0 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.30 Mn |
| Mar 31, 2026 | 9.30 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 3.98 Mn |
| Sep 30, 2025 | 3.98 Mn |
| Jun 30, 2025 | 717,000.00 |
| Jun 30, 2025 | 717,000.00 |
| Mar 31, 2025 | 5.29 Mn |
| Mar 31, 2025 | 5.29 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 9.34 Mn |
| Sep 30, 2024 | 9.34 Mn |
| Jun 30, 2024 | 565,000.00 |
| Jun 30, 2024 | 565,000.00 |
| Mar 31, 2024 | 3.31 Mn |
| Mar 31, 2024 | 3.31 Mn |
| Dec 31, 2023 | -7.42 Mn |
| Dec 31, 2023 | -7.42 Mn |